Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals (Nasdaq: LXRX) presented six posters for Zynquista (sotagliflozin) at the 80th American Diabetes Association Scientific Sessions. In the Phase 3 CKD-3 study, sotagliflozin 400 mg met its primary endpoint, significantly reducing A1C levels by -0.24% compared to placebo. However, the CKD-4 study did not meet its primary endpoint, with no significant A1C reduction observed. The safety profile of sotagliflozin, including incidences of hypoglycemia, was comparable to placebo. Sotagliflozin is approved in the EU for type 1 diabetes in certain patients.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced new data on XERMELO (telotristat ethyl) from a preclinical study assessing its effects on various cancer cell lines, presented alongside the ASCO 2020 annual meeting. The study showed significant tumor growth inhibition in liposarcoma, colon cancer, and cholangiocarcinoma cell lines. This data supports further studies on telotristat ethyl's potential against tryptophan hydroxylase positive cancers. XERMELO is the first approved oral therapy for carcinoid syndrome diarrhea, marketed domestically by Lexicon and internationally by Ipsen.
Summary not available.